Search

CN-122005678-A - Application of shinyleaf yellowhorn leaf active ingredient in preparation of medicine for treating hyperuricemia

CN122005678ACN 122005678 ACN122005678 ACN 122005678ACN-122005678-A

Abstract

The invention relates to the technical field of traditional Chinese medicines, and discloses application of shinyleaf yellowhorn leaf active ingredients in preparation of medicines for treating hyperuricemia. The shinyleaf yellowhorn leaf active ingredients comprise quercetin, rutin and myricetin, wherein the content of the quercetin is 0.2508-0.6719 mg/g, the content of the rutin is 0.6707-1.5831 mg/g, and the content of the myricetin is 0.8002-3.4858 mg/g. The invention firstly defines that myricetin, quercetin and rutin are core effective substances for treating hyperuricemia by shinyleaf yellowhorn leaves, reveals the action mechanisms of multiple targets and multiple paths, and simultaneously shows that the three components have high connectivity in a network and jointly act on key targets such as XOD, ACE, AKR B1 and TNF to prompt that the components do not act singly but act cooperatively by the multiple targets and the multiple paths, thereby providing a new idea for the comprehensive treatment of hyperuricemia from the traditional 'single-target-single-medicine' thinking to the 'multi-component-multiple-target-multiple-path' system regulation mode.

Inventors

  • LI MINHUI
  • ZHENG SHUQI
  • WANG HAIBIN
  • LI XIAOLONG

Assignees

  • 内蒙古自治区中医医院

Dates

Publication Date
20260512
Application Date
20260206

Claims (6)

  1. 1. The application of the shinyleaf yellowhorn leaf active ingredient in preparing the medicine for treating hyperuricemia is characterized in that the shinyleaf yellowhorn leaf active ingredient comprises quercetin, rutin and myricetin, wherein the content of the quercetin is 0.2508-0.6719 mg/g, the content of the rutin is 0.6707-1.5831 mg/g, and the content of the myricetin is 0.8002-3.4858 mg/g.
  2. 2. The use of shinyleaf yellowhorn leaf active ingredient according to claim 1, for the preparation of a medicament for the treatment of hyperuricemia, characterized by being applied to: ① Reducing uric acid, blood sugar, cholesterol, triglyceride, creatinine, glutamic pyruvic transaminase and glutamic oxaloacetic transaminase levels in serum; ② Uric acid production is reduced by inhibiting XOD enzyme activity; ③ Uric acid production is reduced by inhibiting the activities of COX-1 and COX-2 enzymes in an arachidonic acid pathway; ④ By inhibiting the PI3K/AKT pathway, the levels of p-PI3K and p-AKT are reduced, and uric acid generation is reduced; ⑤ The shinyleaf yellowhorn leaf active ingredient protects AML12 and HK2 cells and reduces apoptosis induced by high uric acid.
  3. 3. The application of the shinyleaf yellowhorn leaf active ingredient in preparing the medicines for inhibiting the arachidonic acid pathway and the PI3K/AKT pathway is characterized in that the shinyleaf yellowhorn leaf active ingredient is used for preparing the medicines for treating hyperuricemia.
  4. 4. The shinyleaf yellowhorn extract is characterized by comprising active ingredients of the shinyleaf yellowhorn leaf containing quercetin, rutin and myricetin, wherein the content of the quercetin is 0.2508-0.6719 mg/g, the content of the rutin is 0.6707-1.5831 mg/g, and the content of the myricetin is 0.8002-3.4858 mg/g.
  5. 5. The use of shinyleaf yellowhorn extract according to claim 4 for the preparation of a medicament for the treatment of hyperuricemia, gout, kidney disease or metabolic syndrome.
  6. 6. A medicine for treating hyperuricemia, gout, nephropathy or metabolic syndrome is characterized in that the effective component is shinyleaf yellowhorn extract, the shinyleaf yellowhorn extract comprises shinyleaf yellowhorn leaf active components comprising quercetin, rutin and myricetin, wherein the content of the quercetin is 0.2508-0.6719 mg/g, the content of the rutin is 0.6707-1.5831 mg/g, and the content of the myricetin is 0.8002-3.4858 mg/g.

Description

Application of shinyleaf yellowhorn leaf active ingredient in preparation of medicine for treating hyperuricemia Technical Field The invention relates to the technical field of traditional Chinese medicines, in particular to application of shinyleaf yellowhorn leaf active ingredients in preparing a medicine for treating hyperuricemia. Background The medicines for treating hyperuricemia existing clinically at present can be divided into xanthine oxidase inhibitors such as allopurinol and febuxostat, uric acid excretion promoting medicines such as benzbromarone and probenecid, uricase medicines such as labyrine and novel dual-function medicines such as topiroxostat. Although these drugs have a certain efficacy in controlling uric acid levels, there is still significant hepatorenal toxicity, and serious systemic side effects such as allergic syndrome, gastrointestinal discomfort, rash, etc. occur. And the action mechanism of the medicines is single, and the medicines are difficult to cope with the complex multi-target multi-channel action mechanism of hyperuricemia. The traditional medicine has limitation in research and development, tends to be in a single target-single disease mode, and does not fully consider hyperuricemia as a systemic metabolic disorder disease complexity. Secondly, the safety evaluation of the traditional therapeutic drugs is insufficient, and the problems of long-term organ toxicity accumulation or metabolic disturbance and the like are not comprehensively evaluated. Further, most of the studies are based on animal models, and the essential difference between animal models and humans in uric acid metabolic pathways cannot be considered to be fully appreciated. Finally, although the components of individual plants are reported to have the potential to reduce uric acid levels, studies have remained largely at crude extract levels, lacking explicit active ingredient identification, clinical validation, and the like. The present invention has been made to solve the above problems. Disclosure of Invention The invention aims to provide an application of shinyleaf yellowhorn leaf active ingredients in preparing medicines for treating hyperuricemia, and provides a new thought for comprehensive treatment of hyperuricemia by researching an action mechanism of the shinyleaf yellowhorn leaf active ingredients (myricetin, quercitrin and rutin) through a clinical sample, in-vitro model and proteomics three-in-one research strategy. The invention provides application of shinyleaf yellowhorn leaf active ingredients in preparing a medicament for treating hyperuricemia, wherein the shinyleaf yellowhorn leaf active ingredients comprise quercetin, rutin and myricetin, the content of the quercetin is 0.2508-0.6719 mg/g, the content of the rutin is 0.6707-1.5831 mg/g, and the content of the myricetin is 0.8002-3.4858 mg/g. Further, it is applied to: ① Reducing uric acid, blood sugar, cholesterol, triglyceride, creatinine, glutamic pyruvic transaminase and glutamic oxaloacetic transaminase levels in serum; ② Uric acid production is reduced by inhibiting XOD enzyme activity; ③ Uric acid production is reduced by inhibiting the activities of COX-1 and COX-2 enzymes in an arachidonic acid pathway; ④ By inhibiting the PI3K/AKT pathway, the levels of p-PI3K and p-AKT are reduced, and uric acid generation is reduced; ⑤ The shinyleaf yellowhorn leaf active ingredient protects AML12 and HK2 cells and reduces apoptosis induced by high uric acid. Furthermore, the invention also provides application of the shinyleaf yellowhorn leaf active ingredient in preparing medicaments for inhibiting an arachidonic acid pathway and a PI3K/AKT pathway, and the shinyleaf yellowhorn leaf active ingredient is used for preparing medicaments for treating hyperuricemia. Furthermore, the invention also provides a shinyleaf yellowhorn extract, which comprises active ingredients of shinyleaf yellowhorn leaves containing quercetin, rutin and myricetin, wherein the content of the quercetin is 0.2508-0.6719 mg/g, the content of the rutin is 0.6707-1.5831 mg/g, and the content of the myricetin is 0.8002-3.4858 mg/g. Furthermore, the invention also provides application of the shinyleaf yellowhorn extract in preparing a medicament for treating hyperuricemia, gout, nephropathy or metabolic syndrome. Further, the invention also provides a medicine for treating hyperuricemia, gout, nephropathy or metabolic syndrome, the active ingredient of the medicine is shinyleaf yellowhorn extract, the shinyleaf yellowhorn extract comprises active ingredients of shinyleaf yellowhorn leaf containing quercetin, rutin and myricetin, wherein the content of the quercetin is 0.2508-0.6719 mg/g, the content of the rutin is 0.6707-1.5831 mg/g, and the content of the myricetin is 0.8002-3.4858 mg/g. The application of the shinyleaf yellowhorn leaf active ingredient in preparing the medicine for treating hyperuricemia has the advantages and positive effects that: 1. The inv